SELLAS Life Sciences Group, Inc. (SLS) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 5 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for SLS is $2.80, representing a -42.4% downside from the current price of $4.86. Price targets range from a low of $2.40 to a high of $3.20.
